BioCryst Completes Astria Acquisition, Gains $17 Price Target and Adds Phase 3 HAE Therapy
Evercore ISI resumed coverage of BioCryst Pharmaceuticals with a Buy rating and $17 price target, while Bank of America Securities reaffirmed Buy with a $15 target. BioCryst completed its acquisition of Astria Therapeutics on January 23, adding Phase 3 HAE candidate navenibart and atopic dermatitis program STAR0310.
1. Analyst Ratings Resumed and Reaffirmed
On February 18, Evercore ISI resumed coverage of BioCryst Pharmaceuticals with a Buy rating and a $17.00 price target. On January 27, Bank of America Securities reaffirmed its Buy rating on the stock with a $15.00 target.
2. Acquisition of Astria Therapeutics Completed
BioCryst completed its acquisition of Astria Therapeutics on January 23, initially announced on October 14, 2025. Management stated the deal strengthens its leadership in hereditary angioedema and supports its long-term growth trajectory.
3. Pipeline Expansion with Navenibart and STAR0310
The transaction adds navenibart, a late-stage, long-acting plasma kallikrein inhibitor in Phase 3 development for HAE with potential dosing every three and six months, as well as early-stage atopic dermatitis program STAR0310, for which BioCryst plans to explore strategic alternatives.